glp 1 sequence PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: Semaglutide GLP-1 expression constructs. (a) Sequence

Response rates vary by molecule newer agents such as tirzepatide and semaglutide yield higher responder rates (~86%91%) than older agents such as exenatide or liraglutide (~40%65%) (223) and vary by baseline BMI, sex, and glycemic status, with women and individuals with higher BMI responding better (222, 224)

Berberine may cause gastrointestinal symptoms and interact with diabetes medications, increasing hypoglycaemia risk when combined with insulin or sulfonylureas

PLoS ONE 6 , e19462 (2011)

Researchers are exploring nanoparticle carriers, enzyme inhibitors, and absorption enhancers to make daily oral GLP-1s easier to take and potentially more effective

Their platform is not male-specific but offers more medication variety

A recent propensity-matched cohort study also identified obesity as a risk factor for corticosteroid use, therapy escalation, and colectomy in UC patients (85)